Please assess the completion status of the following clinical trial:

Trial Title: Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who have been diagnosed with type 2 diabetes mellitus.~2. Participants who are being treated with any of the following DPP-4 inhibitors for at least 8 weeks prior to the time of informed consent (Week 0).~   * Sitagliptin : 50 mg once daily~  * Alogliptin : 25 mg once daily~  * Linagliptin : 5 mg once daily~  * Teneligliptin : 20 mg once daily~  * Saxagliptin : 5 mg once daily~3. Participants who were judged by the investigators possible to change the treatment from daily dosing of DPP-4 inhibitor shown in Inclusion Criteria 2 to study drug trelagliptin 100 mg or alogliptin 25 mg.~4. Participants whose glycosylated hemoglobin (HbA1c) value measured within 8 weeks prior to the time of informed consent (Week 0) is below 10.0%.~5. Participants who responded to Diabetes Treatment Satisfaction Questionnaire (DTSQ) at the time of informed consent (Week 0).~6. Participants who were judged by the investigators capable to understand the contents of this clinical research and comply with them.~7. Participants who are able to sign and date the Informed Consent Form before any clinical research procedure begins.~8. Participants who are at least 20 years old at the time of giving the consent.~9. Participants who are classified as outpatients.~Exclusion Criteria:~1. Participants who have a history of taking once-weekly dosing of DPP-4 inhibitor (trelagliptin or omarigliptin).~2. Participants who are being treated with drugs other than those for once-daily oral dosing for the purpose of treatment of chronic complication (for example, BENET® Tablets 75 mg, a therapeutic agent for osteoporosis which is administered once monthly).~3. Participants who are being treated with twice-daily dosing of DPP-4 inhibitor (vildagliptin or anagliptin).~4. Participants who are being treated with anti-diabetic fixed-dose combination pill contained a DPP-4 inhibitor.~5. Participants with moderate or severe renal impairment (for example, participant whose estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73m\^2).~6. Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery).~7. Participants who have a history of hypersensitivity or allergy to DPP-4 inhibitor.~8. Participants with serious heart disease, cerebrovascular disorder, or participants with serious disease in the pancreas, blood, etc.~9. Participants with unstable proliferative diabetic retinopathy.~10. Participants with malignant tumor.~11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.~12. Participants participating in other clinical studies.~13. Participants who have been determined as inappropriate participants by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trelagliptin 100 mg + Alogliptin 25 mg (Type: EXPERIMENTAL): Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
- Alogliptin 25 mg + Trelagliptin 100 mg (Type: EXPERIMENTAL): Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete